CD86 and neoplasm: Comparative transcriptomic analysis has defined higher frequencies of DCs in lung cancer in tumor tissue as compared to non-tumor tissue with less expression of co-stimulatory molecules on their surface (CD40, CD80, CD86 and MHC class II) showing an association with the tumor impairment of DC activation [187,188].